India finds lapses at cough syrup maker linked to Cameroon deaths: Govt official
Advertisement
New Delhi: India has found violations related to manufacturing and laboratory practices at drugmaker Riemann Labs, whose cough syrup was linked to child deaths in Cameroon, a government health official told Reuters on Wednesday.
Indian authorities have stepped up scrutiny of drugmakers after some cough syrups made in the country were linked to deaths of dozens of children overseas.
Riemann Labs did not respond to Reuters requests seeking comment.
Rajesh Bhatia, one of the three directors at Riemann Labs, has told Reuters previously he was not aware of the matter.
Riemann Labs is the fourth Indian cough syrup maker to stop production after regulators found lapses.
Read also: Manufacturing licences of QP Pharmachem, 2 others suspended
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.